Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
The purpose of this study is to compare the safety and efficacy of epirubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide in lymph node negative, estrogen receptor (ER) positive, human epithelial growth factor receptor 2 (HER2) negative breast cancer patients as adjuvant chemotherapy.
Breast Neoplasms
DRUG: Epirubicin|DRUG: Docetaxel|DRUG: cyclophosphamide
number of participants with grade 3-4 neutropenia assessed by CTCAE v4.0, number of participants with neutrophil count less than 1000 per milliliter, up to 16 weeks
number of participants with grade 3-4 leukopenia assessed by CTCAE v4.0, number of participants with leukocyte count less than 2000 per milliliter, up to 16 weeks|number of participants with febrile neutropenia assessed by CTCAE v4.0, number of participants with neutropenia count less than 1000 per milliliter and temperature highe than 38.5℃, up to 16 weeks|breast cancer relapse, number of participants with any locoregional recurrence, contralateral breast cancer or distant metastasis, three years|all cause mortality, number of participans died from all cause, three years
This is a non-inferiority study. According to previous study results, the investigators hypothesize the incidence of grade 3-4 neutropenia is 40%, with a α of 0.05 and β of 0.8, a sample size of 264 cases if needed.